Ignite Creation Date:
2024-05-05 @ 6:37 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00514137
Status:
COMPLETED
Last Update Posted:
2014-05-28
First Post:
2007-08-08
Brief Title:
Sunitinib in Treating Patients With Relapsed Multiple Myeloma
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Phase II Trial of Sunitinib SU11248 in Multiple Myeloma
Status:
COMPLETED
Status Verified Date:
2013-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase II trial is studying how well sunitinib works in treating patients with relapsed multiple myeloma Sunitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer
Detailed Description:
PRIMARY OBJECTIVES
I To assess the number of responses in patients with relapsed multiple myeloma treated with sunitinib sunitinib malate
SECONDARY OBJECTIVES
I To assess the toxicity of sunitinib malate in patients with relapsed multiple myeloma
II To assess time to progression after initial response to sunitinib malate
OUTLINE
Patients receive oral sunitinib malate once daily on days 1-42 Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity
After completion of study treatment patients are followed every 3-6 months for up to 3 years
I To assess the number of responses in patients with relapsed multiple myeloma treated with sunitinib sunitinib malate
SECONDARY OBJECTIVES
I To assess the toxicity of sunitinib malate in patients with relapsed multiple myeloma
II To assess time to progression after initial response to sunitinib malate
OUTLINE
Patients receive oral sunitinib malate once daily on days 1-42 Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity
After completion of study treatment patients are followed every 3-6 months for up to 3 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| N01CM62205 | NIH | PDQ Physician Data Query | httpsreporternihgovquickSearchN01CM62205 |
| MC058F | None | None | None |
| CDR0000560703 | REGISTRY | None | None |